Moleculin Biotech, Inc. (MBRX) Stock Forecast & Price Prediction 2025, 2030, 2040, and 2050
Discover latest Moleculin Biotech, Inc. (MBRX) short-term stock forecast for year 2025, month by month, and long-term MBRX price prediction for years 2025 to 2050. Check MBRX historical stock performance, analyst ratings (Buy, Sell, or Hold), and stay updated with the latest MBRX news and headlines.
1 Month Prediction
$10.21 [368.31%]
3 Month Prediction
$9.52 [336.52%]
6 Month Prediction
$8.26 [279.05%]
1 Year Prediction
$9.86 [352.34%]
3 Year Prediction
$20.82 [855.15%]
5 Year Prediction
$31.83 [1360.26%]
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company that develops treatments for hard-to-treat tumors and viruses.
Their lead drug candidate, Annamycin, is a next-generation anthracycline designed to avoid common treatment issues like multidrug resistance and cardiotoxicity. Annamycin is developed for relapsed or refractory cases, or lung metastases.
The company was founded in 2015 and based in Houston, Texas.
Moleculin Biotech, Inc. (MBRX) Historical Performance
IPO Date
Moleculin Biotech, Inc. (NASDAQ:MBRX) went public on 02 June, 2016.
Change
Since inception, MBRX has decreased by 94.52%. In the last 5 years, MBRX has fallen from $3.66 to $2.18, a massive -40.44% decrease since 2020.
Historical Highs and Lows
In the past 5 years, the stock reached a high of $6.90 and a low of $0.43.
52 Week Range
$0.398
$6.24
The current price $2.18 is not near the 52-week extremes, which means that the stock is neither overbought nor underbought.
MBRX Stock Price History
Based on MBRX stock's historical price data, this table shows how the stock has performed in the last 6 years. Since 2019, the MBRX stock has fallen from $3.66 - $6.9 to $1.51 - $2.18, which is down -71.8%. Currently, the stock follows downward trend.
Here, we have calculated stock range of MBRX, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2020 | $3.66 - $6.9 | $5.2 | -20.74 | 1 Year Change |
| 2021 | $1.86 - $4.97 | $3.33 | -49.25 | 2 Year Change |
| 2022 | $1.0 - $1.78 | $1.41 | -78.51 | 3 Year Change |
| 2023 | $0.43 - $1.26 | $0.75 | -88.57 | 4 Year Change |
| 2024 | $0.5 - $5.91 | $3.0 | -54.28 | 5 Year Change |
| 2025 | $1.51 - $2.18 | $1.85 | -71.8 | 6 Year Change |
MBRX Price Performance
6-Month Performance
MBRX stock dropped by 23.24% in the last six months.
1-Year Performance
The stock has trended downwards by 63.11% in the past year.
3-Year Performance
In the last 3 years, the stock has soared by 22.47%.
5-Year Performance
In the last 5 years, the stock has gone down by 40.44%.
According to Moleculin Biotech, Inc.'s historical data, below graph gives us the exact picture of how the MBRX stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 1 year and a decline in 4 years.
2020
12.90% ↓
2021
61.10% ↓
2022
43.01% ↓
2023
19.06% ↓
2024
98.14% ↑
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
Moleculin Biotech, Inc. (MBRX) Financials & Stock Analysis
Market Capitalization
Moleculin Biotech, Inc. has a market capitalization of $9.06M, which places MBRX in the nano-cap category.
Fundamental Analysis
EPS: $-2.85 (Q3), $-15.15 (1Y)
EPS increased 67.65% since last quarter, and decreased 0.03% since last year.
Net Income: $-10.59 M (Q3), $-29.77 M (1Y)
Net Income increased 145.24% since last quarter, and increased 2.56% since last year.
Free Cash Flow: $-6.11 M (Q3), $-24.23 M (1Y)
Free Cash Flow increased N/A since last quarter, and decreased N/A since last year.
Below, we have listed 12 key indicators for Fundamental analysis for MBRX stock. These indicators help you understand Moleculin Biotech, Inc.'s financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for MBRX stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $1.36 |
| SMA50 | $1.74 |
| SMA200 | $2.87 |
| RSI | 58.22 |
| Beta | 1.94 |
SMA20 < Current Price
This signals MBRX stock is in short-term bullish momentum.
SMA50 < Current Price
This signals MBRX stock is in mid-term bullish momentum.
SMA200 > Current Price
This signals MBRX stock is in long-term bearish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for MBRX stock is Neutral. Out of all indicators, 3 indicates bullish signals, 2 signals bearish trends and 4 gives neutral trends. The MBRX stock forecast was last updated on 18 February, 2025.
Moleculin Biotech, Inc. (MBRX) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to rise to $9.61 by the end of 2025, and can reach around $-1.75 to $-16.79 in 2026. And, the long-term forecast suggests that the stock may further jump to $-9.35 - $8.99 in 2028, and $198.08 - $101.01 by 2031. So, the MBRX stock shows a strong upward trend in the next several years.
Short-term MBRX Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-03 | $10.21 | 368.35% |
| 2025-04 | $9.53 | 337.16% |
| 2025-05 | $9.52 | 336.7% |
| 2025-06 | $8.56 | 292.66% |
| 2025-07 | $8.54 | 291.74% |
| 2025-08 | $8.26 | 278.9% |
| 2025-09 | $8.88 | 307.34% |
| 2025-10 | $8.98 | 311.93% |
| 2025-11 | $9.20 | 322.02% |
| 2025-12 | $9.61 | 340.83% |
In 2025, the MBRX stock price is expected to fluctuate between $8.26 and $10.21. According to the monthly forecast, the stock could rise to $9.61 by December 2024. If compared to the MBRX's current price, the stock could gain 340.83% by the end of this year.
Long-term MBRX Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $-1.75 | $13.75 | $-16.79 | -870.18% |
| 2027 | $-0.98 | $13.63 | $8.94 | 310.09% |
| 2028 | $-9.35 | $74.51 | $8.99 | 312.39% |
| 2029 | $-31.83 | $16.64 | $-24.87 | -1240.83% |
| 2030 | $0.50 | $28.35 | $75.34 | 3355.96% |
| 2031 | $198.08 | $37.55 | $101.01 | 4533.49% |
| 2032 | $-49.29 | $-99.72 | $14.99 | 587.61% |
| 2033 | $-15.39 | $98.42 | $54.19 | 2385.78% |
| 2034 | $98.92 | $106.08 | $15.52 | 611.93% |
| 2035 | $-103.44 | $-133.30 | $178.56 | 8090.83% |
| 2036 | $-34.02 | $83.02 | $-3.36 | -254.13% |
| 2037 | $50.01 | $45.11 | $16.07 | 637.16% |
| 2038 | $124.66 | $241.84 | $235.44 | 10700.0% |
| 2039 | $59.48 | $118.23 | $-71.04 | -3358.72% |
| 2040 | $-3.23 | $73.71 | $123.04 | 5544.04% |
| 2041 | $-162.45 | $176.74 | $-106.85 | -5001.38% |
| 2042 | $-42.02 | $257.91 | $-50.54 | -2418.35% |
| 2043 | $-13.54 | $170.83 | $10.86 | 398.17% |
| 2044 | $42.24 | $155.24 | $95.24 | 4268.81% |
| 2045 | $253.11 | $-98.82 | $340.21 | 15505.96% |
| 2046 | $214.22 | $136.71 | $-27.52 | -1362.39% |
| 2047 | $16.91 | $57.57 | $-134.18 | -6255.05% |
| 2048 | $442.21 | $329.01 | $256.89 | 11683.94% |
| 2049 | $362.73 | $233.73 | $266.56 | 12127.52% |
| 2050 | $414.08 | $-62.14 | $244.19 | 11101.38% |
| 2051 | $348.53 | $-221.11 | $-300.66 | -13891.74% |
Moleculin Biotech, Inc. (MBRX) Stock Price Prediction & Forecast 2025
At the start of 2025, the MBRX stock was at $1.51. Today, it is trading at $2.18, which is 44.37% increase from price at the beginning of the year. By the end of this year, you can expect the stock to reach to $9.61 by December 2025 with a 340.83% change.
Moleculin Biotech, Inc. (MBRX) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant depreciation in the MBRX stock. During this period, the MBRX's price is forecasted to shift from $-1.75 to $75.34, which is -4405.14% loss.
In 2026, the stock would possibly open at $-1.75, descends to $13.75 by mid-year, and wraps up at $-16.79, reflecting a decrease from today's price. Further moving to 2030, the stock can kick off the year at $0.50, drop to $28.35 by mid-year, and finish at $75.34, which is 3356.05% change from current price.
Moleculin Biotech, Inc. (MBRX) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $198.08 to $123.04, which is down 4533.30%
In 2031, we can expect MBRX to fluctuate between $101.01 and $198.08, a shift indicating a 4533.30% gain by year-end compared to current price. And Until 2040, MBRX can likely vary from $123.04 to $-3.23. By the end of 2040, the stock could record a 5544.18% rise from today's stock price.
Moleculin Biotech, Inc. (MBRX) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the MBRX stock can see an a downturn from $-162.45 to $244.19 in this period. In 2041, the stock can experience a low of $176.74 by mid-year, closing the year at $-106.85. This results in a 8007.32% increase from today.
Moving towards the end of 2050, MBRX is projected to open the year at $414.08. The stock may dip to $-62.14 during mid-year and finish the year at $244.19. Compared to the stock's current price, this translates to an overall gain of 11101.27% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
MBRX Competitors
| Ticker | Company | Market Cap | Price | 1m Change | Forecast |
|---|---|---|---|---|---|
| SLDB | Solid Biosciences Inc. | - | $5.52 | 73.58% ▲ | $179.37 ▲ |
| ADTX | Aditxt, Inc. | - | $0.07 | -34.58% ▼ | $1328.57 ▲ |
| CRSP | CRISPR Therapeutics AG | - | $49.72 | 19.55% ▲ | $90.65 ▲ |
| GALT | Galectin Therapeutics Inc. | - | $1.41 | 12.80% ▲ | $268.23 ▲ |
| MNMD | Mind Medicine (MindMed) Inc. | - | $9.89 | 45.66% ▲ | $96.36 ▲ |
Last updated Feb 18 at 1:25 PM
MBRX : Buy, Sell Or Hold?
Analyst Ratings
Based on 1 analysts, 1 rated as a strong buy, 0 recommended a buy, 0 suggested a hold, 0 advised a sell, and 0 indicated a strong sell.So, according to analyst ratings, the recommendation for MBRX stock is Buy.
Expert Analysis
According to MBRX short-term and long-term forecast, Moleculin Biotech, Inc. shares are projected to go up by 11101.38%, and reach a value of $244.19 per share by 2050.
As per technical analysis, indicators show a Neutral sentiment, while Fear & Greed Index stands at 21.428571428571427, which signals Fear. Also, MBRX has recorded 6/30 green days, which reflects a 27.27272727272727% positivity rate with a price volatility of 0.41%.
Plus, Price-to-Earnings (P/E) ratio of 0 suggests that MBRX stock is undervalued. So, Based on MBRX prediction and analysis, it may be the best time to hold MBRX stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "MBRX” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.